Charles River Laboratories CRL Proceeds from maturities of marketable securities
Proceeds from maturities of marketable securities at other companies
Other financials
Where this comes from
Reported directly by Charles River Laboratories in its filing.
Tagged under the XBRL concept us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities.
The official record: Charles River Laboratories’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Charles River Laboratories's proceeds from maturities of marketable securities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Charles River Laboratories's proceeds from maturities of marketable securities?
- Charles River Laboratories (CRL) reported proceeds from maturities of marketable securities of $2.92M in Q1 2026.
- How has Charles River Laboratories's proceeds from maturities of marketable securities changed year-over-year?
- Charles River Laboratories's proceeds from maturities of marketable securities increased by 82.4% year-over-year, from $1.6M to $2.92M.
- What is the long-term trend for Charles River Laboratories's proceeds from maturities of marketable securities?
- Over 2 years (2023 to 2025), Charles River Laboratories's proceeds from maturities of marketable securities has grown at a 16.8% compound annual growth rate (CAGR), from $6.67M to $9.1M.
- What does proceeds from maturities of marketable securities mean?
- Cash received from selling or maturing investment securities.
- How do you interpret proceeds from maturities of marketable securities?
- High proceeds suggest the liquidation of investments to fund operations, debt repayment, or acquisitions, while low proceeds indicate a stable or growing investment portfolio.
- How does proceeds from maturities of marketable securities compare across companies?
- Standard line item in the investing section of the cash flow statement, often grouped with investment activities.